Application of costunolide in preparation of medicine for preventing and / or treating viral myocarditis
By using lecosalinolactone extracted from ycosalin, inhibiting CVB3 viral replication and inflammation, the treatment difficulties of viral myocarditis were solved, significantly slowing myocardial inflammation and viral RNA expression, and providing new therapeutic drugs.
Patent Information
- Application Number
- CN202410997315.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
Smart Images

Figure CN118924737A_ABST
Abstract
Description
Technical Field
[0001] The present invention provides use of costunolide in the preparation of a drug for preventing and / or treating viral myocarditis. Background Art
[0002] Costunolide is a sesquiterpene lactone that was originally extracted from the root of Saussurea lappa Clarke, a plant of the Asteraceae family, and subsequently isolated from a variety of plants. Several preclinical studies have reported that this compound has antioxidant, anti-inflammatory, antibacterial, anti-allergic, bone remodeling, neuroprotective, and anticancer properties. Recently, costunolide has emerged as a potential anticancer agent that can play an anticancer role in a variety of cancers, including colon cancer, breast cancer, prostate cancer, and liver cancer, by inhibiting cell proliferation and inducing cell apoptosis. In addition, costunolide also has significant anti-inflammatory properties. It is reported that the anti-inflammatory activity of costunolide is mainly attributed to its inhibitory effect on the nuclear factor (NF)-κB signaling pathway. Studies have also shown that costunolide is an effective NLRP3 inflammasome selective inhibitor that can covalently bind to the NLRP3 NACHT domain, inhibit NLRP3 ATPase activation, and exert high anti-inflammatory activity in NLRP3-driven diseases. However, the current research on costunolide in antiviral infection is still unclear.
[0003] Myocarditis refers to the clinical and histological manifestations of a range of pathological immune processes in the heart. Patients with acute and chronic myocarditis often present with changes in the number and function of lymphocyte subsets and macrophages, as well as antibody-mediated damage. Myocarditis can be caused by a variety of infectious pathogens, including viruses, bacteria, chlamydia, rickettsia, fungi and protozoa, as well as hypersensitivity reactions. Viruses are the most common infectious pathogens in acute myocarditis. Viral myocarditis has been identified as the main cause of dilated cardiomyopathy (DCM), which can lead to heart failure. The most common pathogen in patients with viral myocarditis is Coxsackievirus B Type 3 (CVB3), accounting for approximately 25%.
[0004] CVB3 is a single-stranded positive-sense RNA virus belonging to the enterovirus family. It is spherical, 22-30nm in diameter, and has a genome length of 7.4kb. The nucleocapsid of CVB3 is composed of four proteins: VP1, VP2, VP3, and VP4. They bind to the (Coxsackievirus and adenovirus receptors) CAR / CD55 / (decay accelerating factor) DAF on the host cell membrane, causing the VP4 and VP1 proteins hidden in the nucleocapsid to be exposed to the surface of the virus, promoting the encapsulation and absorption of CVB3 by the host cell membrane, thereby infecting the host cell. The CVB3 virus mainly infects the heart and pancreatic tissues, but can also infect the brain and liver.
[0005] Viral myocarditis is characterized by cardiac inflammation and excessive inflammatory response after viral infection. Continuous inflammation of the myocardium can lead to myocardial remodeling and eventually develop into DCM, and may cause cardiac fibrosis, leading to decreased cardiac function, heart failure and even death. Therefore, it is of great practical significance to provide a drug that can effectively prevent or treat viral myocarditis. Summary of the invention
[0006] The purpose of the present invention is to provide a method for preparing a method for preventing and / or treating viral myocarditis. The present invention uses the costunolide extracted from Aucklandia lappa as a research object, and intends to illustrate the application of costunolide in treating viral myocarditis. The specific technical scheme is as follows:
[0007] The present invention provides the use of costunolide in the preparation of a drug for preventing and / or treating viral myocarditis. The structure of the costunolide is shown in Formula I:
[0008] The viral myocarditis pathogen is CVB3.
[0009] Preferably, the effective dose of costunolide is 120 mg / kg mouse body weight.
[0010] Preferably, the effective dose of costunolide is 2.0 to 10.0 μM.
[0011] Preferably, the costunolide is used as a traditional Chinese medicine compound to prepare an inhibitor, an inhibitor of the expression of enterovirus structural protein VP1, or an inhibitor of viral RNA in enterovirus-infected cells, or an inhibitor of green fluorescent protein expressed by enterovirus in enterovirus-infected cells.
[0012] Preferably, the effective dose of costunolide is 2.0 μM, 6.0 μM, or 10.0 μM.
[0013] The present invention uses costusin to conduct experiments in vitro and in vivo to inhibit CVB3 virus replication in viral myocarditis and alleviate viral myocarditis inflammation, and concludes that costusin has a significant effect of preventing and / or treating viral myocarditis, and can be used to prepare a drug for treating viral myocarditis.
[0014] The advantage of the invention is that it provides a new source of drugs for treating viral myocarditis. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The present invention will be further described below in conjunction with the accompanying drawings and embodiments:
[0016] Figure 1 This is a diagram showing the cytotoxicity determination of costunolide in Example 1 of the present invention;
[0017] Figure 2 The pharmacodynamic evaluation results of costunolide in Example 2 of the present invention are shown in FIG: changes in mouse body weight;
[0018] Figure 3 This is a diagram showing that costunolide in Example 3 of the present invention can reduce the inflammation of viral myocarditis in mouse heart tissue pathology.
[0019] Figure 4 This is a graph showing that costunolide in Example 4 of the present invention can reduce the expression of viruses at the RNA level in mouse heart tissue.
[0020] Figure 5 This is a graph showing that costunolide in Example 5 of the present invention can reduce the expression of inflammatory factors at the RNA level in mouse heart tissue.
[0021] FIG6 is a graph showing that costunolide inhibits the expression of viruses at the RNA level in Hela cells in Example 6 of the present invention. Figure 6-A Schematic diagram of the treatments, Schematic timeline showing the sequence of CVB3 infection and costunolide treatment; Figure 6-B The QPCR results showed that costunolide significantly inhibited the expression of viral RNA at a concentration of 10 μM;
[0022] FIG. 7 shows that costunolide in Example 7 of the present invention inhibits the expression of CVB3 virus capsid protein VP1 in Hela cells. Figure 7-A Western blot results showed that costunolide inhibited the expression of VP1 protein. Figure 7-B This is the Image J grayscale value statistical graph (quantitated by the ratio of VP1 / α-Tubulin);
[0023] Figure 8 This is a graph showing that costunolide inhibits the expression of viral green fluorescent protein in Example 8 of the present invention;
[0024] Fig. 9 This is a graph showing that costunolide reduces the expression of inflammatory factors at the RNA level after Poly-IC stimulates peritoneal macrophages in Example 9 of the present invention
[0025] FIG. 10 is a diagram showing that costunolide pretreatment inhibits viral expression at the RNA level in Hela cells in Example 10 of the present invention. Figure 10-A Schematic diagram of pretreatment, and schematic timeline showing the sequence of costunolide pretreatment and CVB3 infection. Figure 10-B The results of QPCR showed that pretreatment with costunolide inhibited the expression of viral RNA. DETAILED DESCRIPTION
[0026] The present invention will be further described in detail below in conjunction with the accompanying drawings and implementations. It is to be understood that the specific implementations described herein are only used to explain the relevant content, rather than to limit the present invention. It is also necessary to explain that, for ease of description, only the parts related to the present invention are shown in the accompanying drawings.
[0027] The present invention discloses an application of a compound, and those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0028] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are purchased from commercial channels unless otherwise specified.
[0029] Experimental cells: Hela cells, mouse primary peritoneal macrophages
[0030] The present invention will be further described below in conjunction with embodiments:
[0031] Example 1 Cytotoxicity of Costunolide
[0032] This experiment was analyzed by CCK8 experiment. In order to determine whether costunolide has an effect on cell viability, Hela cells in the logarithmic growth phase were evenly plated in 96-well plates, with approximately 1×10 cells per well. 4 , cultured in a 37°C incubator until the cells were completely attached, and costunolide was diluted with DMEM medium containing 2% FBS and added to each well at concentrations of 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 15.0, and 20.0 μM. An equal volume of PBS was added to the negative control wells, and the cells were gently mixed. Six replicate wells were set for each concentration. After culturing at 37°C for 24 hours, the medium was discarded, and 100 μL of serum-free DMEM medium containing 10% CCK-8 was added to each well in the form of liquid replacement. After 10-20 minutes, the absorbance value of each well was detected at 450 nm.
[0033] Cell viability (cell viability%) = OD value of test well / OD value of control well × 100%
[0034] The cytotoxicity experiment of costunolide showed that costunolide had no toxic effect on Hela cells within the concentration gradient range of 0.5 to 20.0 μM. Therefore, in the subsequent experiments, this study selected a safe concentration range.
[0035] Example 2 Treatment of viral myocarditis caused by CVB3 infection in mice with costunolide 6-8 week old mice were divided into three groups: negative control group: no virus infection; virus group: CVB3 virus infection by intraperitoneal injection at TCID50=1000; costunolide experimental group: 24 hours after infection with CVB3 virus, costunolide was intraperitoneally injected at a dose of 20 mg / kg / day for six consecutive days. (The day of intraperitoneal injection of CVB3 virus infection was recorded as day 0). After infection with CVB3 virus, the weight changes, exercise ability, physiological state, etc. of mice were recorded every day. On the 7th day of virus infection, the mice were decapitated and blood was collected.
[0036] The weight change rate of mice within 7 days showed that the weight of mice in the virus group decreased significantly, while the weight loss of mice in the costunolide experimental group was slowed down. The above results show that costunolide has a significant protective effect on CVB3-infected mice.
[0037] Example 3 Costunolide inhibits the expression of viral RNA in mouse heart tissue
[0038] Mouse heart tissues were collected from the negative control group, virus group, and costunolide experimental group, and RNA was extracted using the Trizol method and reversed into cDNA. Quantitative PCR was then used to detect changes in CVB3 at the RNA level. The results showed that the expression of CVB3 in the heart tissue of mice treated with costunolide was significantly lower than that in the virus group, indicating that costunolide can reduce viral replication in the heart tissue of CVB3-infected mice.
[0039] Example 4 Costunolide alleviates inflammatory infiltration in viral myocarditis in mice.
[0040] The mouse heart tissues of the negative control group, virus group, and costusin lactone experimental group were fixed in 4% paraformaldehyde for 48 hours, and then embedded in paraffin and sliced for hematoxylin-eosin staining (HE staining). First, the mouse heart tissue slices were placed in a 60°C oven for 2 hours and soaked in xylene for dewaxing; then soaked in anhydrous ethanol, 95% ethanol, 90% ethanol, and 80% ethanol for 5 minutes; gently washed with distilled water once, and stained with hematoxylin for 5 minutes; washed with water once; soaked in hydrochloric acid ethanol for 2 seconds; returned to blue in a 55°C water bath for 5 minutes; washed with water once; stained with eosin for 25 seconds; anhydrous ethanol, 95% ethanol, and 80% ethanol for 2 seconds in turn. Finally, dry and seal the slices with neutral quick-drying glue, and observe them with a 10x lens of an upright fluorescence microscope.
[0041] The results showed that compared with the negative control group, local inflammatory infiltration in the heart tissue of mice in the CVB3 group was obvious, while the inflammatory infiltration in the costunolide experimental group was reduced, indicating that costunolide can slow down the inflammatory infiltration in viral myocarditis caused by CVB3 infection.
[0042] Example 5 Costusin reduces the expression of inflammatory factors at the RNA level in viral myocarditis in mice.
[0043] The heart tissues of mice in each group were taken and RNA was extracted using the Trizol method and reversed into cDNA. Then, inflammatory factors such as IL-1β, TNF-α and CXCL-1 were detected by quantitative PCR. The QPCR results showed that the RNA level of inflammatory factors in the heart tissues of mice treated with costunolide was significantly lower than that in the virus group.
[0044] The above results indicate that costunolide can reduce inflammation in viral myocarditis caused by CVB3 infection.
[0045] Example 6 In Hela cells, costusin inhibits the expression of CVB3 viral RNA.
[0046] Hela cells in the logarithmic growth phase were evenly plated in a 12-well plate, with the number of cells per well being approximately 1×10 6 , cultured in a 37°C incubator until the cells were completely attached, 1 ml of DMEM medium containing 2% FBS was added to each well, infected with CVB3 (MOI=0.5), gently shaken, and cultured at 37°C for 1 hour. Then washed three times with PBS, and costunolide was added to each well at a concentration of 2.0, 6.0, and 10.0 μM, and an equal volume of PBS was added to the control well, gently mixed, and cultured at 37°C for 24 hours. Cell RNA was extracted by Trizol method, and then cDNA was obtained by reversal and then quantitative PCR was performed to detect the RNA expression of CVB3.
[0047] The results of QPCR showed that costunolide could significantly reduce the RNA level of CVB3 in Hela cells, and the difference was statistically significant compared with the control group (P<0.05).
[0048] Example 7 In Hela cells, costusin significantly inhibited the expression of VP1 protein.
[0049] Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with the number of cells per well being approximately 1×10 5 , cultured in a 37°C incubator until the cells were completely attached, 500 μl of DMEM medium containing 2% FBS was added to each well, infected with CVB3 (MOI=0.5), gently shaken, and cultured at 37°C for 1 hour. Then washed three times with PBS, and costunolide was added to each well at a concentration of 2.0, 6.0, and 10.0 μM, and an equal volume of PBS was added to the control wells, gently mixed, and cultured at 37°C for 24 hours, and the expression level of VP1 protein was detected by Western blot.
[0050] Western blot results showed that costunolide at 10 μM could significantly reduce the expression of CVB capsid protein VP1 in Hela cells, and showed a dose-dependent manner at 2.0, 6.0, and 10.0 μM, with significant differences compared with the control group (P < 0.05).
[0051] Example 8 In Hela cells, costunolide inhibits the expression of green fluorescence of EGFP-CVB3 virus.
[0052] Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with the number of cells per well being approximately 1×10 5 , cultured in a 37°C incubator until the cells were completely attached, 500 μl of DMEM medium containing 2% FBS was added to each well, infected with CVB3 (MOI=0.5), gently shaken, and cultured at 37°C for 1 hour. Then washed three times with PBS, and costunolide was added to each well at a concentration of 2.0, 6.0, and 10.0 μM, and an equal volume of PBS was added to the control wells, gently mixed, and cultured at 37°C for 24 hours, and the expression of green fluorescent protein was observed using an inverted fluorescence microscope.
[0053] The green fluorescence results showed that costunolide could significantly reduce the expression of green fluorescent protein of EGFP-CVB3 in Hela cells, and it showed a dose-dependency at 2.0, 6.0, 8.0, and 10.0 μM. The above results showed that costunolide could significantly inhibit the replication of CVB3 virus in Hela cells, and it was dose-dependent.
[0054] Example 9 In peritoneal macrophages, costunolide inhibits the expression of inflammatory factors at the RNA level after Poly-IC stimulation.
[0055] Thioglycollate was injected intraperitoneally into mice aged 6-8 weeks. The mice were killed 3 days later and peritoneal macrophages were obtained. The cells were evenly spread on a 24-well plate and cultured in a 37°C incubator until the cells were completely attached to the wall. Each well was stimulated with 100 μg / ml Poly-IC, and an equal volume of PBS was added to the negative control group. At the same time, costunolide was added to the drug-treated group at a concentration of 10.0 μM. The plates were gently mixed and cultured at 37°C for 3 h. Cell RNA was extracted by the Trizol method, and then reversed to obtain cDNA for quantitative PCR to detect the expression of inflammatory factors IL-1β, TNF-α and IL-6 at the RNA level.
[0056] QPCR results showed that the RNA levels of inflammatory factors were significantly reduced after costunolide treatment. The above results indicate that costunolide can alleviate inflammation in viral myocarditis simulated by Poly-IC stimulation of primary peritoneal macrophages.
[0057] Example 10 In Hela cells, pretreatment with costunolide significantly inhibited the expression of viral RNA.
[0058] Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with the number of cells per well being approximately 1×10 5 , cultured in a 37°C incubator until the cells were completely attached, DMEM medium containing 2% FBS and costunolide were added to each well, and the final concentration of costunolide was 2.0, 6.0, and 10.0 μM, respectively. An equal volume of PBS was added to the control wells, and cultured at 37°C for 12 hours. Then, DMEM medium containing 2% FBS was replaced by changing the medium, and CVB3 (MOI=0.5) was infected. After culturing at 37°C for 1 hour, the virus was eluted with PBS and cultured at 37°C for another 12 hours. The total RNA of the cells was extracted by the Trizol method, and then reversed into cDNA and the RNA level of CVB3 was detected by quantitative PCR.
[0059] QPCR results showed that costunolide pretreatment could significantly reduce the expression of CVB3 at the RNA level in Hela cells, and the difference was statistically significant compared with the control group (P < 0.05).
[0060] in conclusion:
[0061] The results of in vivo cytotoxicity experiments showed that costunolide had no toxic effect on Hela cells at a concentration of 20 μM compared with the negative control group (PBS group). The results of in vivo pharmacodynamic experiments showed that mice in the CVB3 virus infection group experienced weight loss, reduced food intake, and slow movements within 4-7 days after infection. The above symptoms were significantly alleviated for mice in the intraperitoneal injection of costunolide group. The results of heart tissue HE staining and QPCR showed that costunolide could significantly alleviate the inflammation in viral myocarditis caused by CVB3 infection. Both in vivo and in vitro results showed that the expression of CVB3 virus at the RNA level in the costunolide treatment group was significantly lower than that in the CVB3 virus infection group, and there was a statistical difference. The results of viral fluorescent protein determination showed that the green fluorescent protein expressed by the virus in the costunolide administration group was significantly reduced compared with the EGFP-CVB3 infection group. The QPCR results showed that costunolide treatment could significantly alleviate the inflammation caused by Poly-IC stimulation of primary peritoneal macrophages. The above results indicate that costunolide has a significant protective effect on mice with viral myocarditis, reducing viral replication and alleviating local inflammation of the heart.
[0062] In summary, the research of the present invention can determine that costunolide can inhibit viral myocarditis and can be used to prepare drugs for preventing and / or treating viral myocarditis.
[0063] It should be understood by those skilled in the art that the above embodiments are only for the purpose of clearly illustrating the present invention, and are not intended to limit the scope of the present invention. For those skilled in the art, other changes or modifications may be made based on the above invention, and these changes or modifications are still within the scope of the present invention.
Claims
1. Use of costunolide in the preparation of a drug for preventing and / or treating viral myocarditis, characterized in that: The structure of the costunolide is shown in Formula I: The viral myocarditis pathogen is CVB3.
2. The use of costunolide according to claim 1 in the preparation of a drug for preventing and / or treating viral myocarditis, characterized in that: The effective dose of the costunolide is 120 mg / kg mouse body weight or 2.0-10.0 μM.
3. Use of costunolide according to claim 2 in the preparation of a drug for preventing and / or treating viral infections, preferably, the effective dose of costunolide is 2.0 μM, 6.0 μM, 8.0 μM, or 10.0 μM.
4. Use of costunolide according to claim 1 in the preparation of a drug for preventing and / or treating viral myocarditis, characterized in that: The costunolide is used as a traditional Chinese medicine compound to prepare an inhibitor, an inhibitor of the expression of enterovirus structural protein VP1, an inhibitor of viral RNA in enterovirus infected cells, or an inhibitor of green fluorescent protein expressed by enterovirus in enterovirus infected cells.
5. Use of costunolide according to claim 4 in the preparation of a drug for preventing and / or treating viral myocarditis, characterized in that: The effective doses of costunolide are 2.0 μM, 6.0 μM and 10.0 μM.
